Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-20T22:46:00.769Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism

Published online by Cambridge University Press:  09 July 2009

R. H. S. Mindham ,
R. Gaind ,
B. H. Anstee  and
Lorna Rimmer
R. H. S. Mindham
Affiliation:
From the Institute of Psychiatry, De Crespigny Park, London, and Bexley Hospital and Guy's Group of Hospitals, London
R. Gaind
Affiliation:
From the Institute of Psychiatry, De Crespigny Park, London, and Bexley Hospital and Guy's Group of Hospitals, London
B. H. Anstee
Affiliation:
From the Institute of Psychiatry, De Crespigny Park, London, and Bexley Hospital and Guy's Group of Hospitals, London
Lorna Rimmer
Affiliation:
From the Institute of Psychiatry, De Crespigny Park, London, and Bexley Hospital and Guy's Group of Hospitals, London
Get access Rights & Permissions [Opens in a new window]

Synopsis

A double-blind comparison was made of the effects of amantadine hydrochloride, orphenadrine hydrochloride, and placebo in the control of the effects on the extrapyramidal nervous system of fluphenazine decanoate. Patients were assessed with regard to the main symptoms of Parkinsonism, the leading clinical signs, performance in walking, writing and squeezing, changes in mood, and unwanted effects of medication. Neither of the pharmacologically active substances was superior to placebo. Attention is drawn to the paucity of evidence for the effectiveness of anti-cholinergic drugs in both Parkinson's disease and in drug-induced Parkinsonism. The special difficulties in performing trials of substances used in relieving the unwanted effects of other drugs are discussed in relationship to defects in methodology in both this and earlier trials. The findings of the present study are not conclusive but show a clear need for further research in this field. The possible theoretical and practical importance of such research is discussed.

Type
Research Article
Information
Psychological Medicine , Volume 2 , Issue 4 , November 1972 , pp. 406 - 413
Copyright
Copyright © Cambridge University Press 1972

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Appleton, D. B., Eadie, M. J., and Sutherland, J. M. (1970). Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial. Medical Journal of Australia, 2, 626–629.CrossRefGoogle ScholarPubMed
Ayd, F. J. Jr., (1961). A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association, 175, 1054–1060.CrossRefGoogle ScholarPubMed
Brumlik, J., Canter, G., de la Torre, R., Mier, M., Petrovick, M., and Boshes, B. (1964). A critical analysis of the effects of trihexyphenidyl (Artane) on the components of the Parkinsonian syndrome. Journal of Nervous and Mental Disease, 138, 424–431.Google Scholar
Cahan, R. B., and Parrish, D. D. (1960). Reversibility of druginduced Parkinsonism. American Journal of Psychiatry, 116, 1022–1023.Google Scholar
Dallos, V., Heathfield, K., Stone, P., and Allen, F. A. D. (1970). Use of amantadme in Parkinson's disease. Results of a double-blind trial. British Medical Journal, 4, 24–26.CrossRefGoogle ScholarPubMed
Drug and Therapeutics Bulletin (1970). Long-acting fluphenazine injections. Drug and Therapeutics Bulletin, 8, 69–71.CrossRefGoogle Scholar
Ekdawi, M. Y., and Fowke, R. (1966). A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism. British Journal of Psychiatry, 112, 633–636.CrossRefGoogle ScholarPubMed
Friedman, M. (1937). The use of ranks to avoid the assumption of normality implicit in the analysis of variance. Journal of the American Statistical Association, 32, 675–701.CrossRefGoogle Scholar
Friedman, M. (1940). A comparison of alternative tests of significance for the problems of m rankings. Annals of Mathematical Statistics, 11, 86–92.CrossRefGoogle Scholar
Gilligan, B. S., Veale, J., and Wodak, J. (1970). Amantadine hydrochloride in the treatment of Parkinson's disease. Medical Journal of Australia, 2, 634–637.Google Scholar
Godwin-Austen, R. B., Tomlinson, E. B., Frears, C. C., and Kok, H. W. L. (1969). Effects of L-dopa in Parkinson's disease. Lancet, 2, 165–168.Google Scholar
Grelak, R. P., Clark, R., Stump, J. M., and Vernier, V. G. (1970). Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science, 169, 203–204.Google Scholar
Hunter, K. R., Stern, G. M., Laurence, D. R., Armitage, P. (1970). Amantadine in Parkinsonism. Lancet, 1, 1127–1129.CrossRefGoogle ScholarPubMed
Mandel, W., and Oliver, W. A. (1961). Withdrawal of maintenance anti-Parkinson drug in the phenothiazine-induced extrapyramidal reaction. American Journal of Psychiatry, 118, 350–351.CrossRefGoogle Scholar
Onuaguluchi, G. (1964). Management of complications. In Parkinsonism, p. 125. Butterworths: London.Google Scholar
Parkes, J. D., Zilkha, K. J., Calver, D. M., and Knill-Jones, R. P. (1970). Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet, 1, 259–262.CrossRefGoogle ScholarPubMed
Schwab, R. S., England, A. C. Jr., Poskanzer, D. C., and Young, R. R. (1969). Amantadine in the treatment of Parkinson's disease. Journal of the American Medical Association, 208, 1168–1170.CrossRefGoogle ScholarPubMed
Strang, R. R. (1965). Kemadrin in the treatment of Parkinsonism: a double blind and one-year follow-up study. Current Medicine and Drugs, 5, No. 8, 27–32.Google ScholarPubMed
Stromberg, U., Svensson, T. H., and Waldeck, B. (1970). On the mode of action of amantadine. Journal of Pharmacy and Pharmacology, 22, 959–962.Google Scholar
Svensson, T. H., and Stromberg, U. (1970). Potentiation by amantadine hydrochloride of L-dopa-induced effects in mice. Journal of Pharmacy and Pharmacology, 22, 639–640.CrossRefGoogle ScholarPubMed
Togo, Y., Hornick, R. B., and Dawbins, A. T. (1968). Studies on induced influenza in man, I. Journal of the American Medical Association, 203, 1089–1094.CrossRefGoogle ScholarPubMed
Vale, S., Angeles Espejel, M., and Cesar Dominquez, J. (1971). Amantadine in depression. Lancet, 2, 437.CrossRefGoogle ScholarPubMed
Vernier, V. G., Harmon, J. B., Stump, J. M., Lynes, T. E., Marvel, J. P., and Smith, D. H. (1969). The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicology and Applied Pharmacology, 15, 642–665.Google Scholar
Wendel, H. A., Snyder, M. T., and Pell, S. (1966). Trial of amantadine in epidemic influenza. Clinical Pharmacology and Therapeutics, 7, 38–43.Google Scholar
Zung, W. W. K. (1965). A self-rating depression scale. Archives of General Psychiatry, 12, 63–70.CrossRefGoogle ScholarPubMed